Here’s what you should know:
1. Orthotaxy is in the midst of developing a differentiated robotic-assisted surgery solution.
2. The proprietary technology is in early-stage development and will address total and partial knee replacements.
3. Johnson & Johnson will leverage the technology to develop cost-effective, time-efficient, user-friendly orthopedic offerings.
4. J&J’s DePuy Synthes Company Group Chairman Ciro Rӧmer said, “Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care.”
More articles on supply chain:
5 key observations on NJ ASC landscape post-‘One-Room Bill”
To prevent the spread of norovirus at the Olympics, athletes told to fist-bump, not shake hands: 4 things to know
Partner at Seaside Surgery Center receives board certification — 4 things to know
